The European Commission recently approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity, according to Novo Nordisk. This regulatory milestone makes Wegovy the first GLP-1 tablet authorized for weight management in the European Union, following previous approvals in the United States, United Kingdom, United Arab Emirates, and Bahrain.
Commercial Impact of Oral Wegovy in Europe
Novo Nordisk’s expansion into oral GLP-1 therapies is a strategic attempt to capture patients who prefer tablets over injectable medications. While the company has already surpassed three million U.S. prescriptions for the oral Wegovy version in just over five months, market analysts view the EU approval as an incremental gain rather than a transformative event. According to Zacks Investment Research, the company faces significant headwinds, including U.S. pricing pressures and softer injectable prescription trends that continue to challenge its overall growth narrative.
Did you know?
Novo Nordisk’s shares have underperformed the broader market, losing 1.1% year-to-date compared to an 11.1% gain in the industry, according to data from Zacks Investment Research.
Competitive Landscape: Novo Nordisk vs. Eli Lilly
The obesity drug market remains dominated by a fierce rivalry between Novo Nordisk and Eli Lilly. Eli Lilly’s Zepbound (tirzepatide) continues to gain traction in the injectable sector, while the company’s oral candidate, Foundayo (orforglipron), poses a long-term threat. Foundayo offers a once-daily dosing regimen without the food or drink restrictions currently associated with Wegovy, which could influence patient adherence rates, as noted by industry analysts.
The competitive balance is further complicated by the Medicare GLP-1 Bridge program in the U.S. While this initiative increases market access and affordability, it provides equal support to both Novo Nordisk and Eli Lilly’s portfolios. As a result, analysts suggest that future market share gains will rely heavily on clinical outcomes, product differentiation, and physician preferences rather than just reimbursement access.
Emerging Biotech Challengers
Beyond the two primary incumbents, smaller firms are moving through clinical pipelines to challenge the market leaders:
- Viking Therapeutics: The company is developing VK2735, a dual GIPR/GLP-1 receptor agonist. Plans are in place to move the oral formulation into phase III development by the fourth quarter of 2026, according to company disclosures.
- Structure Therapeutics: The firm’s phase II ACCESS study for its oral GLP-1 receptor agonist, aleniglipron, showed significant weight loss across all tested doses. A late-stage program is expected to begin in the second half of 2026.
Valuation and Financial Outlook
Financial metrics suggest a cautious outlook for Novo Nordisk. The company’s stock currently trades at 15.14 times forward earnings, which is below its five-year mean of 29.25, according to Zacks Investment Research. Furthermore, earnings estimates for 2026 have been revised downward from $3.47 to $3.38 per share over the last 60 days. The company currently holds a Zacks Rank #5 (Strong Sell), reflecting these downward estimate revisions and competitive pressures.
Pro Tip:
When evaluating pharmaceutical stocks, look beyond regulatory headlines. Long-term performance in the GLP-1 market is increasingly tied to clinical trial data and the ability to maintain supply chain consistency as demand surges.
Frequently Asked Questions
Is oral Wegovy available everywhere?
No. It has received regulatory approval in the U.S., U.K., U.A.E., Bahrain, and recently the European Union. Availability depends on local pharmacy distribution and regional healthcare policies.
How does oral Wegovy compare to Eli Lilly’s oral options?
Eli Lilly’s Foundayo (orforglipron) is currently in development and may offer a convenience advantage through a once-daily dosing regimen that does not require the food or drink restrictions associated with Wegovy’s oral formulation.
What factors are driving current stock performance for Novo Nordisk?
According to Zacks Investment Research, performance is currently driven by a combination of U.S. pricing pressure, competition from Eli Lilly, and fluctuating prescription trends, which have led to downward revisions in earnings estimates for 2026 and 2027.
Are you tracking the latest developments in the obesity drug market? Subscribe to our newsletter for weekly updates on pharmaceutical trends and stock analysis.
Related reading